Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials
Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV)
Company Research
Source: GlobeNewswire
Nes Ziona, Israel, April 13, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the Israel Innovation Authority (IIA) selected the Company’s planned COVID-19 and sepsis clinical programs to receive, in the aggregate, a non-dilutive grant of approximately $1.5 million for the period through the first quarter of 2021. To date, Enlivex has received a total of approximately $4.31 million in grants from the IIA for its historical clinical trials and development. The IIA is an independent, publicly funded agency charged with fostering the development of industrial R&D within the State of Israel. It provides non-dilutive grants that become repayable only through royalties from future sales of products developed with the support of the IIA, and the repayment, if any, is limited to the original grant amount plus interest. Following the positive results of Enlivex’s Phase Ib clinical trial in severe sepsis patien
Show less
Read more
Impact Snapshot
Event Time:
ENLV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENLV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENLV alerts
High impacting Enlivex Therapeutics Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ENLV
News
- Greenberg Traurig Advises Enlivex in $212M Private PlacementPR Web
- Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical DevelopmentGlobeNewswire
- Enlivex Announces Closing of Previously Announced $212,000,000 Private PlacementGlobeNewswire
- Enlivex Therapeutics (NASDAQ:ENLV) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.MarketBeat
- Enlivex Therapeutics (NASDAQ:ENLV) had its "hold" rating reaffirmed by analysts at D. Boral Capital.MarketBeat
ENLV
Sec Filings
- 12/4/25 - Form 6-K
- 11/26/25 - Form 6-K
- 11/24/25 - Form 6-K
- ENLV's page on the SEC website